Drugs.com Clinical Trial ResultsOriginal article
Efzimfotase Alfa Demonstrated Improvements in Bone Health in Treatment-Naïve Pediatric Patients with Hypophosphatasia in MULBERRY Phase III Trial
Phase 3positiveefzimfotase alfaPositive
AI Analysis
Summary
Efzimfotase alfa demonstrated statistically significant and clinically meaningful improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia in the Phase III MULBERRY trial.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Statistically significant and clinically meaningful improvement in bone health in treatment-naïve pediatric patients with hypophosphatasia
Importance:7/10
Sentiment:
0.75
Phase 3 dataenzyme replacement therapypediatric indicationbone healthrare disease
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on June 28, 2026 10:07 AM